drugset / Trial / NCT06779045
A Study of AK-1286 in Patients With Advanced Solid Tumors
NaSequentialOpen-labelTreatment
Summary
This is a phase 1 open label multicenter study to evaluate the maximum tolerance, safety, tolerance and PK of AK-1286 in patients with advanced solid tumors, so as to confirm the recommended phase 2 dose of AK-1286 and obtain the preliminary efficacy information of patients with advanced solid tumors.
Timeline
- Start
- 2025-02-01
- Primary completion
- 2026-09-01
- Completion
- 2026-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AK-1286 | Unknown | 1 mg | Oral |
| Subject | AK-1286 | Unknown | 2 mg | Oral |
| Subject | AK-1286 | Unknown | 4 mg | Oral |
| Subject | AK-1286 | Unknown | 5 mg | Oral |
| Subject | AK-1286 | Unknown | 16 mg | Oral |
| Subject | AK-1286 | Unknown | 24 mg | Oral |
| Subject | AK-1286 | Unknown | 36 mg | Oral |
| Subject | AK-1286 | Unknown | 50 mg | Oral |
Indications
No indication recorded.